As a proof of concept, a study conducted on humans with bevacizumab (i.e., an anti-VEGF monoclonal antibody) showed that inhibition of VEGF inhibited NO production, promoting endothelial dysfunction and hypertension [24]. This evidence concerns the gene VEGFA and Hypertension.